debated at the meeting and supported by a majority of committee members, was that physicians should be specially trained and certified before they could prescribe alosetron.
However, when the FDA formally announced approval six weeks later, that key condition was ignored in favour of a less restrictive plan to allow doctors to prescribe the drug if they personally attested that they were qualified to do so.
Dr Brian Strom, an FDA advisory committee member and professor of biostatistics and epidemiology at the University of Pennsylvania, says the current risk management programme for alosetron risks becoming a "facade," which "may make commercial sense to the company, but not public health sense. The risk-benefit ratio is not worth it, unless the use can be restricted to those who really need it and who are likely to benefit from it-which is a very, very small group." Dr Peter Gross, chairman of the department of internal medicine at Hackensack University Medical Center, New Jersey, says: "The main reason for concern is that this is a drug that has caused fatalities-without much of a warning signal." Despite his concerns, Dr Gross believes the advisory committee's elaborate proposals for certification may have been too idealistic, and he congratulated FDA staff on their handling of the drug.
A third committee member, Dr Mike Cohen from the Institute of Safe Medication Practices in Huntingdon Valley, Pennsylvania, warned that there may be "the same kind of problems in terms of adverse events as we had before, and the drug might have to be withdrawn again." The public statements are the latest in a series of controversies surrounding the drug; the US consumer group Public Citizen had wanted it withdrawn within months of its initial release.
Director of the FDA's Center for Drug Evaluation and Research, Dr Janet Woodcock, defended the decision on prescriber eligibility, saying, "we had to address risk without placing an unnecessary burden on everyone." Asked about the FDA ignoring a key recommendation from its advisers, a spokesperson for GlaxoSmithKline said the committee did not vote on that specific issue.
The concerns come as a former senior consultant with the FDA, Dr Paul Stolley, who was involved in the post-marketing surveillance of alosetron, claims that the FDA has become a "servant of the industry, where dissenting voices are intimidated and ostracised and where scientific debate is repressed." (See Education and debate, p 592; editorial, p 555.)
FDA advisers warn of more deaths if drug is relaunched

Ray Moynihan Washington, DC
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A patient laughs four times during an average consultation with a doctor, according to new research.
But doctors rarely reciprocate, say the researchers, who videotaped 250 consultations in order to count the number of instances of laughter, smiles, and "smiling voices" involving the doctor or the patient or both.
The researchers, from the University of Helsinki, highlight some of the subjects of conversation that triggered laughter in the patients-varicose veins, pain in the leg, yeast infection, finger injury, and cholesterol testingin a report of the study (Journal of Sociolinguistics 2002; 6:207-35) .
The report, "Laughter in medical interaction," shows that in 70% of cases of a patient's laughing there was no response from the doctor. In 20% of cases the doctor did smile, but in only 10% of cases did they laugh. "The patients laugh more than the doctors. We see that the occurrence of laughter seldom leads to its reciprocationlaughing together. It is the patients who do most of the laughing in medical encounters," says the report.
It says that laughter is seen as an invitation to "come closer" and that there can be problems where it is not returned: "Not laughing with someone could indicate such negative features as malalignment and social distance."
The researchers cite various examples of the phenomena. One patient, aged 48, who was having his blood cholesterol level tested told the doctor that his father had died at a young age. The doctor asked him how old he had been and the patient replied: "Forty six. So I only have two more years." The doctor agreed and the patient laughed, but this elicited no response from the doctor. In another case, when a doctor was testing a patient's hearing, he whispered to the patient: "Can you hear this whisper?" The patient whispered back: "Yes" and laughed, also with no response.
Having looked at the evidence, the researchers suggest two theories for the failure of doctors to laugh along with their patients.
Firstly, the doctor's role can be characterised by attributes such as professional cautiousness and neutrality.
"Secondly, the patients mostly used laughter for different kinds of delicate tasks. In these consultations, there are more chances for delicate talks by the patients than the doctordescribing one's drinking, eating habits, undressing." 
